Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Prometheus Biosciences In...

    NASDAQ: RXDX · Real-Time Price · USD
    199.92
    0.18 (0.09%)
    At close: Jun 15, 2023, 10:00 PM

    Prometheus Biosciences Statistics

    Share Statistics

    Prometheus Biosciences has 47.81M shares outstanding. The number of shares has increased by 0% in one year.

    Shares Outstanding

    n/a
    		 47.81M

    Shares Change (YoY)

    n/a
    		 0%

    Shares Change (QoQ)

    n/a
    		 0%

    Owned by Institutions (%)

    n/a
    		 n/a

    Shares Floating

    n/a
    		 33.23M

    Failed to Deliver (FTD) Shares

    n/a
    		 43

    FTD / Avg. Volume

    n/a
    		 n/a

    Short Selling Information

    Short Interest

    n/a
    		 n/a

    Short % of Shares Out

    n/a
    		 n/a

    Short % of Float

    n/a
    		 n/a

    Short Ratio (days to cover)

    n/a
    		 n/a

    Valuation Ratios

    The PE ratio is -31.52 and the forward PE ratio is null. Prometheus Biosciences's PEG ratio is -1.46.

    PE Ratio

    n/a
    		 -31.52

    Forward PE

    n/a
    		 n/a

    PS Ratio

    n/a
    		 656.18

    Forward PS

    n/a
    		 n/a

    PB Ratio

    n/a
    		 6.61

    P/FCF Ratio

    n/a
    		 -35.47

    PEG Ratio

    n/a
    		 -1.46
    Financial Ratio History

    Enterprise Valuation

    Prometheus Biosciences has an Enterprise Value (EV) of 4.21B.

    EV / Sales

    n/a
    		 617.57

    EV / EBITDA

    n/a
    		 -28.85

    EV / EBIT

    n/a
    		 -34.12

    EV / FCF

    n/a
    		 -33.38

    Financial Position

    The company has a current ratio of 31.04, with a Debt / Equity ratio of 0.04.

    Current Ratio

    n/a
    		 31.04

    Quick Ratio

    n/a
    		 31.08

    Debt / Equity

    n/a
    		 0.04

    Debt / EBITDA

    n/a
    		 -0.2

    Debt / FCF

    n/a
    		 -0.23

    Interest Coverage

    n/a
    		 0

    Financial Efficiency

    Return on Equity is -20.97% and Return on Invested Capital is -20.57%.

    Return on Equity

    n/a
    		 -20.97%

    Return on Assets

    n/a
    		 -19.14%

    Return on Invested Capital

    n/a
    		 -20.57%

    Revenue Per Employee

    n/a
    		 $70,195.88

    Profits Per Employee

    n/a
    		 $-1,461,360.82

    Employee Count

    n/a
    		 97

    Asset Turnover

    n/a
    		 0.01

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 -629K

    Effective Tax Rate

    n/a
    		 0.44%

    Stock Price Statistics

    The stock price has increased by 0% in the last 52 weeks. The beta is -0.49, so Prometheus Biosciences's price volatility has been lower than the market average.

    Beta

    n/a
    		 -0.49

    52-Week Price Change

    n/a
    		 n/a

    50-Day Moving Average

    n/a
    		 184.19

    200-Day Moving Average

    n/a
    		 109.6

    Relative Strength Index (RSI)

    n/a
    		 84.04

    Average Volume (20 Days)

    n/a
    		 1,217,911

    Income Statement

    In the last 12 months, Prometheus Biosciences had revenue of 6.81M and earned -141.75M in profits. Earnings per share was -3.49.

    Revenue

    n/a
    		 6.81M

    Gross Profit

    n/a
    		 6.81M

    Operating Income

    n/a
    		 -145.78M

    Net Income

    n/a
    		 -141.75M

    EBITDA

    n/a
    		 -145.78M

    EBIT

    n/a
    		 n/a

    Earnings Per Share (EPS)

    n/a
    		 -3.49
    Full Income Statement

    Balance Sheet

    The company has 292.42M in cash and 29.54M in debt, giving a net cash position of 262.88M.

    Cash & Cash Equivalents

    n/a
    		 292.42M

    Total Debt

    n/a
    		 29.54M

    Net Cash

    n/a
    		 262.88M

    Retained Earnings

    n/a
    		 -331.09M

    Total Assets

    n/a
    		 758.41M

    Working Capital

    n/a
    		 707.06M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -123.25M and capital expenditures -2.7M, giving a free cash flow of -125.96M.

    Operating Cash Flow

    n/a
    		 -123.25M

    Capital Expenditures

    n/a
    		 -2.7M

    Free Cash Flow

    n/a
    		 -125.96M

    FCF Per Share

    n/a
    		 -3.1
    Full Cash Flow Statement

    Margins

    Gross margin is 100%, with operating and profit margins of -2140.96% and -2081.83%.

    Gross Margin

    n/a
    		 100%

    Operating Margin

    n/a
    		 -2140.96%

    Pretax Margin

    n/a
    		 -2081.83%

    Profit Margin

    n/a
    		 -2081.83%

    EBITDA Margin

    n/a
    		 -2140.96%

    EBIT Margin

    n/a
    		 -2140.96%

    FCF Margin

    n/a
    		 -1849.86%

    Dividends & Yields

    RXDX does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 -3.17%

    FCF Yield

    n/a
    		 -2.82%
    Dividend Details

    Analyst Forecast

    Currently there are no analyst rating for RXDX.

    Price Target

    n/a
    		 n/a

    Price Target Difference

    n/a
    		 n/a

    Analyst Consensus

    n/a
    		 n/a

    Analyst Count

    n/a
    		 n/a
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Scores

    Altman Z-Score

    n/a
    		 94.06

    Piotroski F-Score

    n/a
    		 2

    Add to Watchlist